Tenofovir Disoproxil Fumarate/Inarigivir soproxil Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Tenofovir Disoproxil Fumarate/Inarigivir soproxil Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Tenofovir Disoproxil Fumarate/Inarigivir soproxil can convert its Small molecule drug profile and NOD2 x RIG-I x RT biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Tenofovir Disoproxil Fumarate/Inarigivir soproxil (query alias: Tenofovir Disoproxil Fumarate/Inarigivir soproxil) |
|---|---|
| Modality / target | Small molecule drug; NOD2 x RIG-I x RT; NOD2 antagonists, RIG-I stimulants, RT inhibitors |
| Highest global status | Phase 2 |
| Originator | F-Star Therapeutics, Inc. (United States) |
| Active developers | F-Star Therapeutics, Inc. (United States) |
The MCP disease footprint includes Hepatitis B. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07797231 | Phase 3 | Not yet recruiting | 930 | Primary endpoint not disclosed in English source |
| ChiCTR2600129732 | Not Applicable | Not yet recruiting | 50 | Primary endpoint not disclosed in English source |
| NCT07658976 | Phase 3 | Not yet recruiting | 400 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Efficacy and safety of switching to BIC/FTC/TAF plus DRV/cob versus DRV/r, RAL, TDF for maintaining virologic suppression in heavily-experienced people living with HIV-1
Phase 4; n=60; evaluation: Non-inferior. Reported fields: Drug-related adverse events(post-week 24) = 2.0 % ; Drug-related adverse events(post-week 24) = 6.0 %
Evolution of PrEP efficacy: a Bayesian sequential meta-analysis of global trials highlighting the superiority of long-acting injectables
Not Applicable; n=54258; evaluation: Positive. Reported fields: HIV infection proportion = 0.5 % ; HIV infection proportion = <0.1 %
Opti-DOR: 48 week data on DOR/3TC/TDF as an alternative first-line antiretroviral therapy (ART) regimen to integrase inhibitors for people with HIV and BMI>25kg/m2 in a randomised phase 3b non-inferiority study
Phase 3; n=600; evaluation: Non-inferior. Reported fields: HIV-1 RNA <50 copies/mL(Week 48) = 89.0 % ; HIV-1 RNA <50 copies/mL(Week 48) = 90.7 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Tenofovir Disoproxil Fumarate/Inarigivir soproxil addresses Hepatitis B. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 4 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2021-06-29 | Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection | Approved | Financial terms not disclosed |
| 2018-11-29 | JT Terminates Agreements with Gilead Sciences on Exclusive Rights to Develop, Commercialize and Market of Six Anti-HIV Drugs in Japan | Approved | Financial terms not disclosed |
| 2016-11-22 | Reeling From GlobeImmune Hepatitis B Termination with Gilead Sciences, Gilead Faces Merck & Co., GlaxoSmithKline Competition | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Therapeutic index and off-target toxicity
- Resistance biology and biomarker-defined patient selection
- Differentiation from established and emerging standards
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-16. Counts and status fields may change as source records update.
